Background: Paradoxical hidradenitis suppurativa (HS) induced by biologic agents (BA) is scarcely reported.

Objective: We sought to describe the clinical characteristics and outcome of patients developing paradoxical HS under BA.

Methods: This was a multicenter nationwide retrospective study asking physicians to report all cases of HS, confirmed by a dermatologist, occurring during treatment of an inflammatory disease by a BA.

Results: We included 25 patients (15 inflammatory rheumatism, 9 Crohn's disease, 1 psoriasis) treated by 5 BA (adalimumab = 12, infliximab = 6, etanercept = 4, rituximab = 2, tocilizumab = 1). Median duration of BA exposure before HS onset was 12 (range 1-120) months. Patients were mostly Hurley stage I (n = 13) or II (n = 11). Simultaneously to HS or within 1 year, 11 patients developed additional inflammatory diseases, including paradoxical reactions (psoriasis = 9, Crohn's disease = 3, alopecia areata = 1, erythema elevatum diutinum = 1). Complete improvement of HS was more frequently obtained after BA discontinuation or switch (n = 6/10, 60%) rather than maintenance (n = 1/14, 7%). Reintroducing the same BA resulted in HS relapse in 3 of 3 patients.

Limitations: Retrospective nature and lack of complete follow-up for some patients are limitations.

Conclusion: HS is a rare paradoxical adverse effect of BA, but fortuitous association cannot be excluded in some cases. We observed a trend toward better outcome when the BA was discontinued or switched.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2016.01.018DOI Listing

Publication Analysis

Top Keywords

hidradenitis suppurativa
8
biologic agents
8
inflammatory diseases
8
paradoxical
5
patients
5
suppurativa unrecognized
4
unrecognized paradoxical
4
paradoxical biologic
4
agents chronic
4
inflammatory
4

Similar Publications

Response to Chen et al., "Comments on the increased risk of hidradenitis suppurativa in patients with human papillomavirus infection".

J Am Acad Dermatol

December 2024

Department and Graduate Institute of Business Administration, National Taiwan University, Taipei, Taiwan; Department of Pharmacology, Chung Shan Medical University, Taichung, Taiwan; Orthopedics Department, Chi-Mei Medical Center, Tainan, Taiwan. Electronic address:

View Article and Find Full Text PDF

Comments on the increased risk of hidradenitis suppurativa in patients with human papillomavirus infection.

J Am Acad Dermatol

December 2024

Department of Dermatology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Dermatology, National Yang Ming Chao Tung University, Taipei, Taiwan; School of Medicine, National Yang Ming Chao Tung University, Taipei, Taiwan. Electronic address:

View Article and Find Full Text PDF

Sporadic Hidradenitis Suppurativa (spHS) is a multifactorial disease in which genetic predisposition is intertwined with environmental factors. Due to the still to date limited knowledge of spHS genetics, we calculated Polygenic scores (PGS) to study the genetic underpinnings that contribute to spHS within European demographic. 256 spHS patients and 1686 healthy controls were analyzed across 6 European clinical centers.

View Article and Find Full Text PDF

Background: Mutations in gamma-secretase complex (GSC) genes are associated with hidradenitis suppurativa (HS), and toll-like receptor (TLR) 2 is elevated in HS lesions. However, it remains unclear whether TLR2 is upregulated in the skin lesions of patients with HS with GSC gene variants, and the role of its upregulation in the pathogenesis of this disease are unknown.

Objective: To investigate the role of TLR2 upregulation in NCSTN and PSENEN knockdown keratinocytes.

View Article and Find Full Text PDF

the present multicenter retrospective study aimed to evaluate the efficacy and safety of intra-class switching between interleukin-17A (IL-17A) inhibitors, specifically from ixekizumab to secukinumab, in patients with plaque psoriasis. this study included 11 patients (6 male, 5 female) who had previously received ixekizumab and then were switched to secukinumab. Patients' PASI, DLQI, and pain VAS (in those with psoriatic arthritis) were evaluated at weeks 16, 24, 54, and 98.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!